Pharmaceuticals

The Spanish biotech firm strengthens its IP for a novel aggression treatment, targeting a growing multi-billion dollar Japanese CNS market.

A lawsuit seeks to block drastic cuts to Florida's ADAP program, which could strip thousands of life-saving HIV medication and insurance by March 1.

With its third Forbes nod, Jackson Healthcare's mix of strategic growth, tech, and culture reveals a model for navigating the healthcare crisis.

Promising Phase 2 data for a potential first-in-class neuropathic corneal pain therapy to be showcased, offering new hope for a debilitating condition.

Incyte's Zynyz gets a key EU panel's nod, offering a breakthrough for advanced anal canal cancer patients after decades of limited treatment options.

Known for non-opioid pain relief, Scilex is diversifying with a major investment in a stealthy diagnostic firm, hinting at a new data-driven strategy.

An Austin-based tech company's platform, which integrates into doctors' workflows, has cut prescription costs for nearly 60,000 Ohio residents.

Ruxolitinib cream's landmark approval in China marks a new era for vitiligo treatment, impacting patients, markets, and regulatory policy.

Facing a cash crunch after a major clinical trial setback, the cancer vaccine developer is exploring a sale or merger, putting its pipeline at risk.

A new dual-action tablet shows major promise for prostate cancer patients with BRCA mutations, poised to change the standard of care in Europe.

The market for drugs like Ozempic and Wegovy is set to explode, fueled by new oral pills, expanded uses for heart and liver disease, and fierce competition.

Tonix Pharmaceuticals' newly approved drug, TONMYA, offers a breakthrough for millions, using unique science to combat the chronic pain of fibromyalgia.

A new global survey reveals millions of women are unprepared for menopause's skin impact. One company is now pushing for a new standard in research.

New data on Idorsia's lucerastat reveals potential to slow kidney decline in Fabry disease, offering a new path for an oral, genotype-independent therapy.

With a Super Bowl ad, NFL icons like Rob Gronkowski and Novartis are demystifying prostate cancer screening to save lives. Relax, it's a blood test.

With its acquisition offer falling short of a majority, Cycle Pharma extends its tender for Applied Therapeutics, leaving the company's fate in the balance.

Industry leaders at the GenScript Global Forum agree: the era of AI experimentation is over. Now, the hard work of scaling and building trust begins.

A new report warns US drug price controls could mirror Canada's struggles, delaying access to new medicines. Is America trading innovation for affordability?

A German biotech's novel oral drug for herpes is moving to Phase 2 trials, offering new hope against a widespread and often resistant virus.

ENA Respiratory's INNA-051 nasal spray, a virus-agnostic shield, has begun Phase II trials, offering new hope for high-risk communities.